{"id":56504,"date":"2026-02-06T21:08:05","date_gmt":"2026-02-06T13:08:05","guid":{"rendered":"https:\/\/flcube.com\/?p=56504"},"modified":"2026-02-06T21:08:06","modified_gmt":"2026-02-06T13:08:06","slug":"bristol-myers-squibb-growth-portfolio-drives-17-revenue-increase-in-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56504","title":{"rendered":"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bristol-Myers Squibb<\/strong> (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE:\u202fBMY<\/a>) reported fourth\u2011quarter 2025 revenue of <strong>USD\u202f12.5\u202fbillion<\/strong>, up <strong>1% year\u2011on\u2011year (YOY)<\/strong>, while full\u2011year revenue reached <strong>USD\u202f48.2\u202fbillion<\/strong>, relatively flat compared to 2024. The <strong>Growth Portfolio<\/strong> surged <strong>17%<\/strong> to <strong>USD\u202f26.4\u202fbillion<\/strong>, driven by immuno\u2011oncology, Breyanzi, Reblozyl, and Camzyos, offsetting a <strong>15% decline<\/strong> in the Legacy Portfolio.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q4\u202f2025<\/th><th>Full\u2011Year\u202f2025<\/th><th>YOY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>USD\u202f12.5\u202fB<\/td><td>USD\u202f48.2\u202fB<\/td><td>Flat<\/td><\/tr><tr><td><strong>US Market<\/strong><\/td><td>\u2014<\/td><td>USD\u202f33.3\u202fB<\/td><td>\u2014<\/td><\/tr><tr><td><strong>International<\/strong><\/td><td>\u2014<\/td><td>USD\u202f14.9\u202fB<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Growth Portfolio<\/strong><\/td><td>USD\u202f7.4\u202fB<\/td><td>USD\u202f26.4\u202fB<\/td><td>+17%<\/td><\/tr><tr><td><strong>Legacy Portfolio<\/strong><\/td><td>USD\u202f5.1\u202fB<\/td><td>USD\u202f21.8\u202fB<\/td><td>-15%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-growth-portfolio-performance\">Growth Portfolio Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Indication<\/th><th>2025 Sales (USD\u202fB)<\/th><th>YOY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>Opdivo (nivolumab)<\/strong><\/td><td>Immuno\u2011oncology (PD\u20111)<\/td><td>10.049<\/td><td>\u2014<\/td><\/tr><tr><td><strong>Opdivo Qvantig<\/strong><\/td><td>Subcutaneous PD\u20111<\/td><td>0.238<\/td><td>New launch<\/td><\/tr><tr><td><strong>Breyanzi (lisocabtagene maraleucel)<\/strong><\/td><td>CD19 CAR\u2011T<\/td><td>1.358<\/td><td>+82%<\/td><\/tr><tr><td><strong>Reblozyl (luspatercept)<\/strong><\/td><td>Anemia<\/td><td>2.327<\/td><td>+31%<\/td><\/tr><tr><td><strong>Camzyos (mavacamten)<\/strong><\/td><td>Obstructive HCM<\/td><td>1.068<\/td><td>+77%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-legacy-portfolio-amp-key-products\">Legacy Portfolio &amp; Key Products<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eliquis (apixaban):<\/strong> Generated <strong>USD\u202f14.443\u202fbillion<\/strong>, up <strong>8%<\/strong> YOY<\/li>\n\n\n\n<li><strong>Generic Impact:<\/strong> Continued erosion across remainder of Legacy Portfolio and higher US government channel rebates offset Eliquis growth<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Transformation:<\/strong> Growth Portfolio now represents <strong>55%<\/strong> of total revenue, up from <strong>47%<\/strong> in 2024, demonstrating successful transition from legacy assets<\/li>\n\n\n\n<li><strong>Immuno\u2011Oncology Leadership:<\/strong> Opdivo franchise maintains <strong>$10\u202fbillion+<\/strong> annual sales; subcutaneous Qvantig formulation addresses patient convenience and competitive positioning<\/li>\n\n\n\n<li><strong>Cell Therapy Acceleration:<\/strong> Breyanzi\u2019s <strong>82% growth<\/strong> validates CAR\u2011T manufacturing scale\u2011up and expanded indications<\/li>\n\n\n\n<li><strong>Cardiovascular Expansion:<\/strong> Camzyos\u2019s <strong>77% growth<\/strong> in HCM establishes new therapeutic category leadership<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Management expects Growth Portfolio to exceed <strong>60%<\/strong> of revenue by 2026, driven by Reblozyl expansion and new immuno\u2011oncology combinations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue projections, portfolio transformation, and commercial prospects for Bristol Myers Squibb. Actual results may differ due to competitive dynamics, regulatory approvals, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/BMY-Q4-2025-Earnings-Press-Release.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BMY-Q4-2025-Earnings-Press-Release.\"><\/object><a id=\"wp-block-file--media-97ca2792-1ee8-4800-9b40-ef38d7f387c2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/BMY-Q4-2025-Earnings-Press-Release.pdf\">BMY-Q4-2025-Earnings-Press-Release<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/BMY-Q4-2025-Earnings-Press-Release.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-97ca2792-1ee8-4800-9b40-ef38d7f387c2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb (BMS, NYSE:\u202fBMY) reported fourth\u2011quarter 2025 revenue of USD\u202f12.5\u202fbillion, up 1% year\u2011on\u2011year (YOY), while&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56506,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[429,428,27,849],"class_list":["post-56504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-bms","tag-bristol-myers-squibb","tag-finanical-reports","tag-nyse-bmy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb (BMS, NYSE:\u202fBMY) reported fourth\u2011quarter 2025 revenue of USD\u202f12.5\u202fbillion, up 1% year\u2011on\u2011year (YOY), while full\u2011year revenue reached USD\u202f48.2\u202fbillion, relatively flat compared to 2024. The Growth Portfolio surged 17% to USD\u202f26.4\u202fbillion, driven by immuno\u2011oncology, Breyanzi, Reblozyl, and Camzyos, offsetting a 15% decline in the Legacy Portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56504\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb (BMS, NYSE:\u202fBMY) reported fourth\u2011quarter 2025 revenue of USD\u202f12.5\u202fbillion, up 1% year\u2011on\u2011year (YOY), while full\u2011year revenue reached USD\u202f48.2\u202fbillion, relatively flat compared to 2024. The Growth Portfolio surged 17% to USD\u202f26.4\u202fbillion, driven by immuno\u2011oncology, Breyanzi, Reblozyl, and Camzyos, offsetting a 15% decline in the Legacy Portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56504\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T13:08:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T13:08:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025\",\"datePublished\":\"2026-02-06T13:08:05+00:00\",\"dateModified\":\"2026-02-06T13:08:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504\"},\"wordCount\":285,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0602.webp\",\"keywords\":[\"BMS\",\"Bristol-Myers Squibb\",\"Finanical Reports\",\"NYSE: BMY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56504#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56504\",\"name\":\"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0602.webp\",\"datePublished\":\"2026-02-06T13:08:05+00:00\",\"dateModified\":\"2026-02-06T13:08:06+00:00\",\"description\":\"Bristol-Myers Squibb (BMS, NYSE:\u202fBMY) reported fourth\u2011quarter 2025 revenue of USD\u202f12.5\u202fbillion, up 1% year\u2011on\u2011year (YOY), while full\u2011year revenue reached USD\u202f48.2\u202fbillion, relatively flat compared to 2024. The Growth Portfolio surged 17% to USD\u202f26.4\u202fbillion, driven by immuno\u2011oncology, Breyanzi, Reblozyl, and Camzyos, offsetting a 15% decline in the Legacy Portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56504\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56504#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"Bristol-Myers Squibb (BMS, NYSE:\u202fBMY) reported fourth\u2011quarter 2025 revenue of USD\u202f12.5\u202fbillion, up 1% year\u2011on\u2011year (YOY), while full\u2011year revenue reached USD\u202f48.2\u202fbillion, relatively flat compared to 2024. The Growth Portfolio surged 17% to USD\u202f26.4\u202fbillion, driven by immuno\u2011oncology, Breyanzi, Reblozyl, and Camzyos, offsetting a 15% decline in the Legacy Portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56504","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025","og_description":"Bristol-Myers Squibb (BMS, NYSE:\u202fBMY) reported fourth\u2011quarter 2025 revenue of USD\u202f12.5\u202fbillion, up 1% year\u2011on\u2011year (YOY), while full\u2011year revenue reached USD\u202f48.2\u202fbillion, relatively flat compared to 2024. The Growth Portfolio surged 17% to USD\u202f26.4\u202fbillion, driven by immuno\u2011oncology, Breyanzi, Reblozyl, and Camzyos, offsetting a 15% decline in the Legacy Portfolio.","og_url":"https:\/\/flcube.com\/?p=56504","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T13:08:05+00:00","article_modified_time":"2026-02-06T13:08:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56504#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56504"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025","datePublished":"2026-02-06T13:08:05+00:00","dateModified":"2026-02-06T13:08:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56504"},"wordCount":285,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56504#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0602.webp","keywords":["BMS","Bristol-Myers Squibb","Finanical Reports","NYSE: BMY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56504#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56504","url":"https:\/\/flcube.com\/?p=56504","name":"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56504#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56504#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0602.webp","datePublished":"2026-02-06T13:08:05+00:00","dateModified":"2026-02-06T13:08:06+00:00","description":"Bristol-Myers Squibb (BMS, NYSE:\u202fBMY) reported fourth\u2011quarter 2025 revenue of USD\u202f12.5\u202fbillion, up 1% year\u2011on\u2011year (YOY), while full\u2011year revenue reached USD\u202f48.2\u202fbillion, relatively flat compared to 2024. The Growth Portfolio surged 17% to USD\u202f26.4\u202fbillion, driven by immuno\u2011oncology, Breyanzi, Reblozyl, and Camzyos, offsetting a 15% decline in the Legacy Portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56504#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56504"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56504#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0602.webp","width":1080,"height":608,"caption":"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56504#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb Growth Portfolio Drives 17% Revenue Increase in 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56504"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56504\/revisions"}],"predecessor-version":[{"id":56507,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56504\/revisions\/56507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56506"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}